指南与共识血管炎其他结缔组织病

2025 EULAR 风湿性多肌痛与原发性大血管炎管理建议

2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis.
指南 / 共识 · Ann Rheum Dis · 2026-07-21

该建议更新了风湿性多肌痛(PMR)、巨细胞动脉炎(GCA)和大动脉炎(TAK)的管理推荐。疑似GCA应在24小时内转诊专科,确诊前即可启动糖皮质激素;多数疑似PMR或TAK可待确诊后治疗。诱导缓解期泼尼松等效剂量PMR为15-25 mg/日,GCA/TAK为40-60 mg/日,并提供了减量方案及辅助治疗选择。

要点

  • 疑似GCA应在24小时内转诊专科评估,确诊前即可启动糖皮质激素。
  • PMR诱导缓解泼尼松等效剂量15-25 mg/日,GCA或TAK为40-60 mg/日。
  • PMR/GCA可选IL-6受体抑制剂,GCA可选upadacitinib,甲氨蝶呤为替代。

核心结论

  • 更新后的单一套实用建议和算法涵盖了PMR和大血管炎的管理。

研究设计与样本

  • 按照EULAR标准操作流程,系统文献综述识别了PMR(2015版)和GCA/TAK(2018版)更新以来发表的数据。
  • 国际工作组讨论证据并经结构化投票,制定了总体原则、建议和质量指标。

主要发现

  • 工作组就4条总体原则、12条建议和2项质量指标达成一致。
  • 所有总体原则和建议均获得高水平的同意。

关键数值与推荐

  • 所有疑似PMR、GCA或TAK的患者应转诊专科评估,疑似GCA者应在24小时内转诊。
  • 临床高度怀疑GCA的患者,在等待确诊检查结果期间应不延迟启动糖皮质激素治疗。
  • 多数疑似PMR或TAK患者,糖皮质激素治疗可延迟至诊断确认后。
  • 诱导缓解时,PMR的糖皮质激素起始剂量为泼尼松等效15-25 mg/日,GCA或TAK为40-60 mg/日。
  • PMR和GCA可选IL-6受体抑制剂,GCA可选upadacitinib,甲氨蝶呤可作为替代;TAK所有患者应联合糖皮质激素使用保激素药物。

临床怎么用

  • 对疑似GCA患者应立即转诊并在确诊前启动糖皮质激素,疑似PMR或TAK者可待确诊后治疗。
  • 按推荐剂量起始糖皮质激素并遵循减量指导,对特定PMR/GCA患者加用辅助治疗,TAK患者均联合保激素药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to update the European Alliance of Associations for Rheumatology (EULAR) recommendations for management of polymyalgia rheumatica (PMR), giant cell arteritis (GCA), and Takayasu arteritis (TAK). METHODS: Following EULAR standard operating procedures, systematic literature reviews identified data published since the previous versions for PMR (2015) and for GCA/TAK (2018). An international task force discussed the evidence, and following a structured voting process, created overarching principles, recommendations, and quality indicators. RESULTS: The task force agreed on 4 overarching principles, 12 recommendations, and 2 quality indicators. All patients with suspected PMR, GCA, or TAK should be referred for specialist assessment and those with suspected GCA within 24 hours. In patients with a strong clinical suspicion of GCA, treatment with glucocorticoids (GCs) should be commenced without delay, while waiting for the results of confirmatory investigations. For most patients with suspected PMR or TAK, treatment with GC can be delayed until the diagnosis is confirmed. For induction of remission, GC should be initiated at a dose of 15 to 25 mg/day prednisone-equivalent for PMR and 40 to 60 mg for GCA or TAK. Guidance on GC tapering is provided. Adjunctive therapy is recommended for selected patients with PMR or GCA using either interleukin (IL)-6 receptor inhibitors for PMR and GCA or upadacitinib for GCA. Methotrexate may be an alternative. GC-sparing agents should be given in combination with GC to all patients with TAK. All overarching principles and recommendations met with high levels of agreement. CONCLUSIONS: Updated guidance on management of PMR and large vessel vasculitis is provided in a single set of practical recommendations and algorithms.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Mukhtyar CB, Nikiphorou E, Bartoletti A, et al. 2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis. Ann Rheum Dis. 2026. PMID: 42481270. doi:10.1016/j.ard.2026.06.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。